Kimberly-Clark Corporation (KMB) is a Nasdaq-listed consumer staples stock—not an exchange-traded fund—best known for Huggies, Kleenex, Scott, Kotex, and Depend. After a volatile year shaped by a major acquisition and a portfolio restructuring, the shares closed near $108 in late October 2026, and investors are weighing whether a recovery can carry the stock toward a $128 target.
This analysis is based on about a dozen individually verified, current price targets from named firms, ranging from $90 to $162. The arithmetic mean of all of those targets is roughly $116, only about 7% above the latest price—below the threshold needed for a meaningful central target. Because the overall average sits so close to the market price, the $128 figure is calculated as the average of the seven targets that are above the current price.
Bullish targets cluster near the top of the range: RBC Capital at $162, Rothschild & Co Redburn at $142, and Buy-rated targets from Bank of America ($120), Piper Sandler ($118), and Freedom Broker ($121). Neutral or Hold-rated views sit mid-range—UBS at $115, Evercore ISI at $115, Deutsche Bank at $108, Barclays at $105, and Wells Fargo at $100. The most cautious call is Citi's Sell rating with a $90 target. This wide spread reflects genuine disagreement: bulls argue the Kenvue deal and productivity savings will expand margins, while skeptics warn that revenue growth remains the binding constraint.
Kimberly-Clark shares traded near $108.32 at the October 20, 2026 close, with a 52-week range of $92.42 to $123.09. Reaching $128 would require a gain of about 18% from current levels—a substantial move that would also take the stock above its prior 52-week high.
The path would most likely run through continued gross-margin gains and improved EPS (earnings per share) rather than rapid sales growth. In the quarter ended June 30, 2026, net sales rose just 0.6% year over year, while gross profit increased 10.1% and adjusted EPS rose 10.4%—a pattern of flat revenue but stronger profitability. Sustaining that trend while investors gain confidence in the Kenvue integration would be central to any move toward $128.
The stock's 50-day and 200-day moving averages both sit near $102–$103, meaning the shares are trading modestly above their medium- and long-term trend lines. The 52-week high near $123 acts as a key resistance level, and the $128 target lies just beyond it. On the downside, the $97–$100 zone served as a consolidation area in late September and early October, with the 52-week low at $92.42 providing a deeper support level.
Analyst price targets generally reflect a roughly 12-month horizon, though individual assumptions vary. The next major catalyst is Kimberly-Clark's quarterly earnings report, estimated for around November 5, 2026. Investors should watch organic sales growth, gross-margin trends, progress and financing costs on the Kenvue integration, updated guidance, and any changes to analyst targets. Macroeconomic factors such as pulp and commodity costs, currency moves, and interest rates also matter for a low-beta staples name carrying meaningful debt.
For traders seeking a more dynamic, data-driven view, AI Daily Buy/Sell Signals from Tickeron uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, track existing positions, and spot changing trends more efficiently than manual screening. For a stock like KMB, where analyst targets diverge sharply, an AI-based signal can provide a useful, real-time complement to traditional research.
Reaching $128 would require Kimberly-Clark to rise roughly 18% and set a new 52-week high. The target is derived from the average of analyst targets above the current price, and it is supported by credible arguments around margin expansion, productivity savings, and the Kenvue acquisition. However, the wide $90–$162 target range and the overall mean near $116 show that the Street is far from unanimous, with weak organic growth and acquisition execution the principal obstacles. The next earnings report and the pace of Kenvue-related synergies will be the most important near-term signposts. As with any stock, no outcome is guaranteed, and the target represents analyst expectations rather than a promise of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, KMB has been loosely correlated with CL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if KMB jumps, then CL could also see price increases.